34046-07-6

Usage

Uses

Used in Pharmaceutical Industry:
Z-N-(N-BETA-BOC-AMINOETHYL)-GLY-OH is used as a key building block in solid-phase peptide synthesis for the preparation of peptide and protein drugs. Its incorporation allows for the creation of complex peptide sequences that can be utilized in the development of therapeutic agents targeting a variety of medical conditions.
Used in Biochemical Research:
In the realm of biochemical research, Z-Glycine serves as an essential reagent for studying the structure, function, and interactions of peptides and proteins. Its presence in experimental setups aids in understanding the fundamental biological processes and mechanisms involving these macromolecules.
Used in Enzymology:
Z-N-(N-BETA-BOC-AMINOETHYL)-GLY-OH is employed as a substrate or inhibitor in enzymatic reactions to investigate the catalytic properties and specificity of enzymes involved in peptide bond formation and hydrolysis.
Used in Cell Biology:
This peptide derivative is utilized in cell biology to explore the interactions of peptides and proteins with cellular components, such as receptors, channels, and transporters, providing insights into cellular signaling pathways and mechanisms.
Overall, Z-N-(N-BETA-BOC-AMINOETHYL)-GLY-OH is a versatile compound with applications spanning across various scientific disciplines, contributing to the advancement of knowledge and the development of novel therapeutics in the fields of medicine, biochemistry, and cell biology.

Upstream product

• 90495-99-1 N-(2-tert-butoxycarbonylaminoethyl)aminoacetic acid 
• 501-53-1 benzyl chloroformate 
• 57260-73-8 N-BOC-1,2-diaminoethane 
• 24123-14-6 N-(2-Aminoethyl)glycine 
• 13303-10-1 tert-Butyl 4-nitrophenyl carbonate 
• 72648-80-7 ethyl 2-[2-(tert-butoxycarbonylamino)ethyl-[3-[[4-(4,5-difluoro-2-methylsulfanyl-phenyl)phenoxy]methyl]benzoyl]amino]acetate 
• 72648-81-8 C₁₉H₂₈N₂O₆ 
• 128421-86-3 methyl N-(2-(tert-butyloxycarbonyl)aminoethyl)glycinate 
• 79-11-8 chloroacetic acid 

Downstream Products

• 34027-30-0 Boc-(z)-AEG-L-phenylalaninmethylester 
• 24123-14-6 N-(2-Aminoethyl)glycine 
• 289684-72-6 {(2-{2-[benzyloxycarbonyl-(2-tert-butoxycarbonylamino-ethyl)-amino]-acetylamino}-ethyl)-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-amino}-acetic acid methyl ester 
• 1413927-62-4 C₃₁H₄₂N₄O₉ 
• 1460306-66-4 C₂₀H₂₈N₂O₆ 
• 34029-18-0 (S)-2-(2-{Benzyloxycarbonyl-[2-((S)-2-benzyloxycarbonylamino-3-phenyl-propionylamino)-ethyl]-amino}-acetylamino)-3-phenyl-propionic acid methyl ester 
• 289684-52-2 3,9-dioxo-1,4,7,10tetraaza-cyclododecane-1,7-dicarboxylic acid 1-benzyl ester 7-(9H-fluoren-9-ylmethyl) ester 
• 289684-54-4 7-[(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-acetyl]-3,9-dioxo-1,4,7,10tetraaza-cyclododecane-1-carboxylic acid benzyl ester 
• 289684-53-3 3,9-Dioxo-1,4,7,10-tetraaza-cyclododecane-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Towards a circular bis-peptide nucleic acid

En route to a circular bis-PNA molecule, we have synthesized and characterized the DNA binding of several "clamp"-type bis-PNAs. In order to incorporate charge into a circular PNA, a new linker based on the achiral 2-aminoethylglycine has been used.

Peptide Nucleic Acid with Double Face: Homothymine-Homocytosine Bimodal Cα-PNA (bm-Cα-PNA) Forms a Double Duplex of the bm-PNA2:DNA Triplex

Cα-bimodal peptide nucleic acids (bm-Cα-PNA) are PNAs with two faces and are designed homologues of PNAs in which each aminoethylglycine (aeg) repeating unit in the standard PNA backbone hosts a second nucleobase at Cα through a spacer chain with a triazole linker. Such bm-Cα-PNA with mixed sequences can form double duplexes by simultaneous binding to two complementary DNAs, one to the base sequence on t-amide side and the other to the bases on the Cα side chain. The synthesis of bm-Cα-PNA with homothymine (T7) on the t-amide face and homocytosine (C5) on the Cα side chain through the triazole linker was achieved by solid phase synthesis with the global click reaction. In the presence of complementary DNAs dA8 and dG6 at neutral pH, bm-Cα-PNA 1 forms a higher order pentameric double duplex of a triplex composed of two bm-Cα-PNA-C5:dG5 duplexes built on a core (bm-Cα-PNA-T7)2:dA8 triplex. Circular dichroism studies showed that assembly can be achieved by either triplex first and duplex later or vice versa. Isothermal titration calorimetry data indicated that the assembly is driven by favorable enthalpy. These results validate concurrent multiple complex formation by bimodal PNAs with additional nucleobases at Cα or Cγon the aeg-PNA backbone and open up ways to design programmed supramolecular assemblies.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS

The conformationally restricted, spatially defined macrocyclic ring system of formula (I) is constituted by three distinct molecular parts: Template A, conformation Modulator B and Bridge C. Macrocycles described by this ring system I are readily manufactured by parallel synthesis or combinatorial chemistry in solution or on solid phase. They are designed to interact with a variety of specific biological target classes, examples being agonistic or antagonistic activity on G-protein coupled receptors (GPCRs), inhibitory activity on enzymes or antimicrobial activity. In particular, these macrocycles show inhibitory activity on endothelin converting enzyme of subtype 1 (ECE-1 ) and/or the cysteine protease cathepsin S (CatS), and/or act as antagonists of the oxytocin (OT) receptor, thyrotropin-releasing hormone (TRH) receptor and/or leukotriene B4 (LTB4) receptor, and/or as agonists of the bombesin 3 (BB3) receptor, and/or show antimicrobial activity against at least one bacterial strain. Thus they are showing great potential as medicaments for a variety of diseases.

Convenient synthesis and cyclization of dimeric abasic PNA

The synthesis of an abasic PNA-based dimer block has been achieved. An alkyl chain stapling the two base sites conformationally restricts the PNA backbone, and serves as an example of preorganization by direct base site linkage. Other possible examples of

Synthetic procedures for peptide nucleic acids

A novel class of compounds, known as peptide nucleic acids, bind complementary ssDNA and RNA strands more strongly than a corresponding DNA. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide backbone through a suitable linker.

Peptide nucleic acids having antibacterial activity

Methods of and compositions for killing or inhibiting the growth of a bacteria are disclosed. The methods comprise the use of peptide nucleic acids that are targeted to mRNA and/or rRNA. In certain embodiments, methods include the use of one or more separate antibiotics.

Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility

A novel class of compounds known as peptide nucleic acids, bind complementary DNA and RNA strands, and generally do so more strongly than the corresponding DNA or RNA strands while exhibiting increased sequence specificity and solubility. The peptide nucleic acids comprise ligands selected from a group consisting of naturally-occurring nucleobases and non-naturally-occurring nucleobases, including 2,6-diaminopurine, attached to a polyamide backbone, and contain alkyl amine side chains.

Linked peptide nucleic acids

Novel peptide nucleic acids and novel linked peptide nucleic acids, form triple stranded structures with nucleic acids. The peptide nucleic acids include ligands such as naturally occurring nucleobases attached to the peptide backbone through a suitable linker. Other nucleobases including C-pyrimidines and iso-pyrimidines can be used as the ligands in Hoogsteen strands to increase binding affinity. Two peptide nucleic acid strands are joined together with a linker to form a bis-peptide nucleic acid. The individual strands of the peptide nucleic acids in the bis compounds can be oriented either parallel or antiparallel to each other.

Peptide nucleic acids

Novel peptide nucleic acids and novel linked peptide nucleic acids, form triple stranded structures with nucleic acids. The peptide nucleic acids include ligands such as naturally occurring nucleobases attached to a peptide backbone through a suitable linker. Other nucleobases including C-pyrimidines and iso-pyrimidines can be used as the ligands in Hoogsteen strands to increase binding affinity. Two peptide nucleic acid strands are joined together with a linker to form a bis-peptide nucleic acid. The individual strands of the peptide nucleic acids in the bis compounds can be orientated either parallel or antiparallel to each other.